SCHEDULE 13G: Sio Capital Management Discloses 6.9% Stake in PMV Pharmaceuticals

Sio Capital Management, LLC has reported a 6.9% beneficial ownership stake in PMV Pharmaceuticals, Inc. as of December 31, 2024, according to a recent Schedule 13G filing.

Summary

• Sio Capital Management, LLC reported beneficial ownership of 3,572,167 shares of PMV Pharmaceuticals, Inc. common stock.
• This stake represents 6.90% of the Issuer's common stock outstanding.
• The percentage is calculated based on 51,747,130 shares of common stock outstanding as of November 6, 2024, as previously reported by PMV Pharmaceuticals in its Form 10-Q.
• Sio Capital Management, LLC holds shared voting power and shared dispositive power over all 3,572,167 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or outlook. It merely reports an institutional stake.

Positives

• The disclosure of a 6.9% stake by Sio Capital Management, an investment adviser, indicates institutional interest and confidence in PMV Pharmaceuticals, Inc.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding PMV Pharmaceuticals, Inc.'s future performance or strategic outlook.

Industry Context

This Schedule 13G filing is a routine disclosure of a significant institutional ownership stake, common across all industries. For a biotechnology or pharmaceutical company like PMV Pharmaceuticals, institutional investment is a critical component of its capital structure and can signal investor confidence in its research and development pipeline or market potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Sio Capital Management, LLC may be viewed positively, potentially signaling a vote of confidence in the company's prospects.

Key Dates

Keywords

PMV Pharmaceuticals, Sio Capital Management, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing